Drug interactions between Eminase and Miradon
| Results for the following 2 drugs: |
|---|
| Eminase (anistreplase) |
| Miradon (anisindione) |
Interactions between your selected drugs
anisindione ↔ anistreplase
Applies to:Miradon (anisindione) and Eminase (anistreplase)
MONITOR CLOSELY: Although warfarin is commonly administered for the prevention of embolism in certain patients following thrombolytic therapy (e.g., myocardial infarction), oral anticoagulants may increase the risk of serious bleeding when administered before, during, or after fibrinolytic agents. Cholesterol embolization syndrome has also been reported rarely with thrombolytics and anticoagulants, when used alone or in combination.
MANAGEMENT: Alteplase is contraindicated in patients with acute ischemic stroke who are currently taking oral anticoagulants and have an INR greater than 1.7. For other indications, risk versus benefit should be carefully weighed if patients who are currently taking oral anticoagulants (INR 2 to 3) are to receive thrombolytic therapy and patient selection should adhere to currently recommended criteria. Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites. If oral anticoagulants are initiated following thrombolytic therapy, the dosage should be adjusted as appropriate to maintain therapeutic INR values. Patients should be closely monitored for clinical and laboratory signs of bleeding.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
